Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Phase 2 Completed 59 enrolled H. Lee Moffitt Cancer Center and Research Institute National Pediatric Cancer Foundation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if nab-paclitaxel combined with gemcitabine prevents the formation or growth of tumors in participants with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma and to measure the length of time during and after treatment that their disease does not get worse. Researchers also want to find out if nab-paclitaxel combined with gemcitabine is safe and tolerable.

Timeline

Start: 2016-10-25
Primary completion: 2024-11-19
Completion: 2025-02-17

Publications

Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Nab-paclitaxel	Small molecule	125 mg/m2	Intravenous

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Summary

Timeline

Publications

Drugs

Indications